Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized mRNA Neoantigen Vaccine + Adebrelimab in Resected NSCLC
NCT06735508Phase 1Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Vaccine mRNA, mRNA Vaccines, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RGL-270 in non-small cell lung cancer (NSCLC), sponsored by Guangdong Provincial People's Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicities, Incidence and Severity of Adverse Events and 1 more. Planned start Jan 2025; status: not yet recruiting.
02
Drugs
RGL-270
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06735508.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06735508.